References
- Volberding P A, Lagakos S W, Koch M A, Pettinelli C, Myers M W, Booth D K, Balfour H H, Reichman R C, Bartlett J A, Hirsch M S, Murphy R L, Hardy W D, Soeiro R, Fischel M A, Bartlett J G, Merigan T C, Hyslop N E, Richman D D, Valentine F T, Corey L. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD-4 positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–949
- Collier A C, Bozzette S, Coombs R W, Causey D M, Schoenfeld D A, Spector S A, Pettinelli C B, Davies G, Richman D D, Leedom J M, Kidd P, Corey L. A pilot study of low dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015–1021
- Richmann D D, Fischel M A, Grieco M H, Gottlieb M S, Volberding P A, Laskin O L, Leedom J M, Groopman J E, Mildvan D, Hirsch M S, Jackson G G, Durack D T, Nusinoff-Lehrman S, The A ZT, Group Collaborative Working. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. N Engl J Med 1987; 317: 192–198
- Fischel M A, Parker C B, Pettinelli C, Wulfsohn M, Hirsch M S, Collier A C, Antoniskis D, Ho M, Richman D D, Fuchs E, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1009–1014
- Fischel M A, Richman D D, Hansen N. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112: 727–737
- Nordic Medical Research Councils' HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992; 304: 13–17
- Furth P A, Kazakis A M. Nail pigmentation changes associated with azidothymidine (zidovudine). Ann Intern Med 1987; 107: 350
- Panwalker A P. Nail pigmentation in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1987; 107: 943–944
- Vaiopoulos G, Mangakis J, Karabinis A, Kourtis A, Fourtounis P, Fessas P. Pigmentation and azidothymidine. Ann Intern Med 1988; 108: 777
- Azon-Masoliver A, Mallolas J, Gatell J, Castel T. Zidovudine induced nail pigmentation. Arch Dermatol 1988; 124: 1570–1571
- Fisher C A, McPoland P R. Azidothymidine-induced nail pigmentation. Cutis 1989; 43: 552–554
- Bendick C, Rasokat H, Steigleder G K. Azidothymidine induced hyperpigmentation of skin and nails. Arch Dermatol 1989; 125: 1285–1286
- Greenberg R G, Berger T G. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol 1990; 22: 327–330
- Anders K H, Abele D C. Development of nail pigmentation during zidovudine therapy. J Am Acad Dermatol 1989; 21: 792–793
- Groark S P, Hood A F, Nelson K. Nail pigmentation associated with zidovudine. J Am Acad Dermatol 1989; 21: 1032–1033
- Grau-Massanes M, Millan F, Ferber M I, Pujol C, Alegre V A, Salavert M, Navarro V, Allaya A. Pigmented nail bands and mucocutaneous pigmentation in HIV positive patients treated with zidovudine. J Am Acad Dermatol 1990; 44: 687–688
- Tadini G, Dorso M, Cusini M, Alessi E, Cinque P. Oral mucosa pigmentation. A new side effect of azidothymidine therapy in patients with acquired immunodeficiency syndrome. Arch Dermatol 1991; 127: 267–268
- Don P C, Fusco F, Fried P, Batterman A, Duncanson F P, Lenox T H, Klein N C. Nail dyschromia associated with zidovudine. Ann Intern Med 1990; 112: 145–146
- Baran R, Dawber R P. Diseases of the nails and their management. Blackwell Scientific, Oxford 1984; 249
- Daniel C R, Scher R K. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol 1984; 10: 250–258
- Daniel C R. Nail pigmentation abnormalities. In: Dermatologic clinics; The nail. Philadelphia: W. B. Saunders 1985; 3: 431–433
- Roth R J, Baker G, Levin J. An animal model for the study of azidothymidine induced hyperpigmentation. Lab Invest 1991; 64: 437–439